Dacomitinib
Dacomitinib is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR.
Dacomitinib has advanced to several Phase III clinical trials. The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing.
In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC were announced.
Dacomitinib was approved in the United States in 2018, in Japan in 2019 and in the European Union authorized by the European Medicines Agency in 2019 for the treatment of non-small cell lung cancer with EGFR gene mutation.
